Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
NCT00334750
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Subjects diagnosed at study visit or within 3 months of visit with OH
- OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)
- No prior treatment for OH or OAG
- No prior ocular surgery or history of ocular trauma
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Cypress, California
- Garden Grove, California
- Gardena, California
- Long Beach, California
- Los Angeles, California
- Los Angeles, California
- Newport Beach, California
- Pasadena, California
- Calgary, Alberta
- Edmonton, Alberta
- Edmonton, Alberta
- Nanaimo, British Columbia
- Vancouver, British Columbia
- Williams Lake, British Columbia
- Winnipeg, Manitoba
- Sydney, Nova Scotia
- Brampton, Ontario
- Hamilton, Ontario
- London, Ontario
- Mississauga, Ontario
- Oakville, Ontario
- Oakville, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Sherbrooke, Quebec
- Saskatoon, Saskatchewan
- Albi,
- Ambert,
- Amboise,
- Angers,
- Antibes,
- Aubenas,
- Belfort,
- Bergerac,
- Bernay,
- Bethune,
- Beziers,
- Blagnac,
- Bordeaux,
- Bordeaux,
- Bougival,
- Boulogne-Billancourt,
- Brest,
- Bry Sur Marne,
- Carentan,
- Cenon,
- Chamalieres,
- Chantilly,
- Chartres,
- Chateaubriant,
- Chateaulin,
- Clermont-Ferrand,
- Condom,
- Coulommiers,
- Courbevoie,
- Creil,
- Deauville,
- Deuil la Barre,
- Douai,
- Draveil,
- Enghien Les Bains,
- Epernay,
- Fontaine,
- Frejus,
- Gennevilliers,
- Gradignan,
- Grasse,
- Grasse,
- Grenoble,
- Grenoble,
- Guingamp,
- Haguenau,
- Herblay,
- Hyeres,
- Issy Les Moulineaux,
- Ivry Sur Seine,
- Jarville La Malgrange,
- Joigny,
- Juvisy Sur Orge,
- La Rochelle,
- La Talaudiere,
- La Trinite,
- Landerneau,
- Langon,
- Lannion,
- Laon,
- Le Creuzot,
- Le Havre,
- Le Mans,
- Le peage de Rousillon,
- Le Quesnoy,
- Lesneven,
- Lille,
- Livry Gargan,
- Lunel,
- Luneville,
- Luxeuil les Bains,
- Lyon,
- Lyon,
- Lyon,
- Lyon,
- Maisons Laffitte,
- Marcq en Baroeul,
- Marignanne,
- Marseille,
- Marseille,
- Marseille,
- MArseille,
- Marseille,
- Meyzieu,
- Montauban,
- Montceau Les Mines,
- Montpellier,
- Mulhouse,
- Nantes,
- Nice,
- Nice,
- Nimes Cedex 2,
- Nimes,
- Niort,
- Nogent Sur Marne,
- Noyon,
- Orleans,
- Oullins,
- Pantin,
- Paray le Monial,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Paris,
- Pauillac,
- Pau,
- Perigueux,
- Perros Girec,
- Pezenas,
- Poissy,
- Poitiers,
- Pont de Cheruy,
- Pornic,
- Port De Bouc,
- Quimper,
- Reims,
- Rochefort,
- Romilly sur Seine,
- Saint Die des Vosges,
- Saint Etienne,
- Saint Gaudens,
- Saint Savine,
- Saintes,
- Salon de Provence,
- Sartrouville,
- Sens,
- Sessiney Pariset,
- Sete,
- Soissons,
- St Chamond,
- St Etienne,
- St Michel Sur Orge,
- St. Brieuc,
- St. Lo,
- Strasbourg,
- Strasbourg,
- Suresnes,
- Talence,
- Thiers,
- Toulon,
- Toulouse,
- Toulouse,
- Tourcoing,
- Tournefeuille,
- Tours,
- Trelissac,
- Tremblay en France,
- Triel Sur Seine,
- Troyes,
- Valenciennes,
- Vannes,
- Vauvert,
- Veauche,
- Velaux,
- Vendargues,
- Venissieux Cedex,
- Viarmes,
- Vienne,
- Villeneuve D'Ascq,
- Villeneuve la Garenne,
- Villeneuve Saint Georges,
- Villeparisis,
- Villepinte,
- Villiers Le Bel,
- Vizille,
- Voiron,
- Wattrelos,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title | Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada | |||
Official Title | Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada | |||
Brief Summary | This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada. | |||
Detailed Description | Not Provided | |||
Study Type | Observational | |||
Study Design | Observational Model: Cohort Time Perspective: Prospective | |||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Non-Probability Sample | |||
Study Population | Canadian population | |||
Condition |
| |||
Intervention | Other: There is no intervention in this study.
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada. | |||
Study Groups/Cohorts | There is no intervention in this study
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada. Intervention: Other: There is no intervention in this study. | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status | Completed | |||
Actual Enrollment | 410 | |||
Original Enrollment | 400 | |||
Actual Study Completion Date | April 2009 | |||
Actual Primary Completion Date | April 2009 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender |
| |||
Ages | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | Canada | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT00334750 | |||
Other Study ID Numbers | A6111125 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. ) | |||
Study Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |||
Collaborators | Not Provided | |||
Investigators |
| |||
PRS Account | Pfizer | |||
Verification Date | September 2010 |